

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr **AA-AMILZIDE**

Amiloride Hydrochloride and Hydrochlorothiazide Tablets

Tablet, 5 mg / 50 mg, Oral

USP

Diuretic-Antihypertensive

AA PHARMA INC
1165 Creditstone Road Unit #1
Vaughan, Ontario
L4K 4N7
www.aapharma.ca/en/

Date of Initial Authorization:
MAR 13, 2019

Date of Revision:
MAR 15, 2023

Submission Control Number: 268237

RECENT MAJOR LABEL CHANGES

| | |
|---|---------|
| 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment | 03/2023 |
| 4 DOSAGE AND ADMINISTRATION, 4.4 Administration | 03/2023 |
| 7 WARNINGS AND PRECAUTIONS, Driving and Operating Machinery | 03/2023 |
| 7 WARNINGS AND PRECAUTIONS, Respiratory | 03/2023 |
| 7 WARNINGS AND PRECAUTIONS, Ophthalmologic | 03/2023 |

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

| | |
|---|----------|
| RECENT MAJOR LABEL CHANGES | 2 |
| TABLE OF CONTENTS | 2 |
| PART I: HEALTH PROFESSIONAL INFORMATION | 4 |
| 1 INDICATIONS | 4 |
| 1.1 Pediatrics..... | 4 |
| 1.2 Geriatrics..... | 4 |
| 2 CONTRAINDICATIONS | 4 |
| 3 SERIOUS WARNINGS AND PRECAUTIONS BOX | 5 |
| 4 DOSAGE AND ADMINISTRATION | 5 |
| 4.1 Dosing Considerations | 5 |
| 4.2 Recommended Dose and Dosage Adjustment | 6 |
| 4.4 Administration | 7 |
| 4.5 Missed Dose | 7 |
| 5 OVERDOSAGE | 7 |
| 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING | 8 |
| 7 WARNINGS AND PRECAUTIONS | 8 |
| 7.1 Special Populations | 12 |
| 7.1.1 Pregnant Women..... | 12 |
| 7.1.2 Breast-feeding..... | 13 |
| 7.1.3 Pediatrics..... | 13 |
| 7.1.4 Geriatrics..... | 13 |

| | | |
|--|---|-----------|
| 8 | ADVERSE REACTIONS..... | 13 |
| 8.1 | Adverse Reaction Overview | 13 |
| 8.2 | Clinical Trials Adverse Reactions..... | 13 |
| 8.5 | Post-Market Adverse Reactions..... | 16 |
| 9 | DRUG INTERACTIONS | 16 |
| 9.1 | Serious Drug Interactions | 16 |
| 9.3 | Drug-Behavioural Interactions..... | 17 |
| 9.4 | Drug-Drug Interactions | 17 |
| 9.5 | Drug-Food Interactions..... | 22 |
| 9.6 | Drug-Herb Interactions | 22 |
| 9.7 | Drug-Laboratory Test Interactions..... | 22 |
| 10 | CLINICAL PHARMACOLOGY..... | 22 |
| 10.1 | Mechanism of Action | 22 |
| 10.2 | Pharmacodynamics..... | 23 |
| 10.3 | Pharmacokinetics..... | 24 |
| 11 | STORAGE, STABILITY AND DISPOSAL..... | 26 |
| 12 | SPECIAL HANDLING INSTRUCTIONS..... | 26 |
| PART II: SCIENTIFIC INFORMATION | | 27 |
| 13 | PHARMACEUTICAL INFORMATION | 27 |
| 14 | CLINICAL TRIALS | 28 |
| 14.2 | Comparative Bioavailability Studies | 28 |
| 15 | MICROBIOLOGY | 28 |
| 16 | NON-CLINICAL TOXICOLOGY | 28 |
| 17 | SUPPORTING PRODUCT MONOGRAPHS..... | 31 |
| PATIENT MEDICATION INFORMATION | | 32 |

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

AA-AMILZIDE (amiloride hydrochloride and hydrochlorothiazide tablet) is indicated in the maintenance therapy of patients with:

- hepatic cirrhosis with ascites and edema.
- edema of cardiac origin or with arterial hypertension who are hypokalemic or in whom maintenance of normal potassium levels is considered to be clinically important i.e., digitalized patients, patients in whom adequate dietary intake of potassium is not feasible or patients with cardiac arrhythmias.

Use in Hepatic Cirrhosis with Ascites and Edema

Amiloride hydrochloride used alone may provide satisfactory diuresis with diminished potassium loss and with a reduced risk of metabolic alkalosis. In resistant cases amiloride hydrochloride may be used with kaliuretic-diuretic agents to help produce satisfactory diuresis, while maintaining a more balanced serum electrolyte pattern. As with all therapy for the ascites of hepatic cirrhosis, gradual weight loss and avoidance of electrolyte imbalance are the chief objectives (See [7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic](#)).

1.1 Pediatrics

Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of AA-AMILZIDE in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. (See [7.1.3 Pediatrics](#)).

1.2 Geriatrics

Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. (See [3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Hyperkalemia](#)).

2 CONTRAINDICATIONS

AA-AMILZIDE (amiloride hydrochloride and hydrochlorothiazide) is contraindicated in the following conditions:

- **Hyperkalemia:** AA-AMILZIDE should not be used in the presence of elevated serum potassium levels (See [7 WARNINGS AND PRECAUTIONS, Hyperkalemia](#)).
- **Antikaliuretic Therapy or Potassium Salts:** Other antikaliuretic agents and potassium supplements are contraindicated in patients receiving AA-AMILZIDE (such combination

therapy is commonly associated with rapid increases in plasma potassium levels).

- **Impaired Renal Function:** Anuria, acute renal failure, severe or progressive renal disease and diabetic nephropathy are contraindications to the use of AA-AMILZIDE (See [7 WARNINGS AND PRECAUTIONS, Renal, Impaired Renal Function](#)).
- Patients who are hypersensitive to this drug or to other sulfonamide-derived drugs or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

- **Hyperkalemia:** Hyperkalemia, i.e. serum potassium levels over 5.5 mEq per litre, has been observed in some patients who received amiloride hydrochloride either alone or with diuretics. This has been noted particularly in elderly patients, in diabetic patients, and in hospitalized patients with hepatic cirrhosis or cardiac edema who had known renal impairment, were seriously ill, or were receiving vigorous diuretic therapy. Since fatalities have occurred in such patients, they should be monitored carefully for clinical, laboratory and electrocardiographic (ECG) evidence of hyperkalemia and for acidosis. Monitoring of the serum potassium level is important because hyperkalemia is not always associated with an abnormal ECG.
- Warning signs or symptoms of hyperkalemia include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, shock, and ECG abnormalities (See [7 WARNINGS AND PRECAUTIONS, Hyperkalemia](#)).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- Optimal dosage should be established by the individual titration of the components.
- Maintenance doses may be lower than those required to initiate diuresis; therefore, reduction in the daily dosage should be attempted when the patient's weight is stabilized. In cirrhotic patients, gradual weight reduction is especially desirable to reduce the likelihood of untoward reactions associated with diuretic therapy.
- Fixed-dose combination drugs are not indicated for initial therapy. Patients should be titrated on the individual drugs. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs.

4.2 Recommended Dose and Dosage Adjustment

- **Hepatic Cirrhosis with Ascites and Edema**

The usual maintenance dose of AA-AMILZIDE is 1 tablet given once a day. The dosage should not exceed 4 tablets a day in single or divided doses.

- **Edema of Cardiac Origin**

The usual maintenance dose of AA-AMILZIDE is 1 or 2 tablets given once a day or in divided doses. The dosage should not exceed 4 tablets a day. Therapy may be on an intermittent basis.

- **Hypertension**

The usual maintenance dosage is 1 or 2 tablets given once a day or in divided doses. The dosage should not exceed 4 tablets a day.

- **Pediatrics**

Health Canada has not authorized an indication for pediatric use (See [7.1.3 Pediatrics](#)).

- **Drug discontinuation**

If diagnosis of Acute Respiratory Distress Symptom (ARDS) is suspected, AA-AMILZIDE should be withdrawn and appropriate treatment given.

If hyperkalemia occurs in patients taking AA-AMILZIDE the drug should be discontinued immediately.

Amiloride hydrochloride should be discontinued at least 3 days before glucose tolerance testing.

Thiazides should be discontinued before carrying out tests for parathyroid function.

If increasing azotemia and oliguria occur during treatment, AA-AMILZIDE should be discontinued.

If photosensitivity reactions occur during treatment with hydrochlorothiazide-containing drugs, treatment should be stopped.

4.4 Administration

Tablets are for oral administration. AA-AMILZIDE can be taken with or without food. If AA-AMILZIDE causes upset stomach, take it with food or milk.

4.5 Missed Dose

If the patient misses a dose, inform the patient to skip the missed dose and take the next dose at the regular dosing schedule.

5 OVERDOSAGE

Symptoms

No data is available in regard to overdosage in humans with AA-AMILZIDE (amiloride hydrochloride and hydrochlorothiazide) or with the amiloride hydrochloride component.

The most common signs and symptoms to be expected from overdosage with AA-AMILZIDE are dehydration and electrolyte imbalance. Serum electrolytes should be carefully monitored with special attention to potassium levels.

Cardiac arrhythmias may be caused by abnormal potassium levels. Digitalized patients are especially prone to arrhythmias.

Treatment

No specific information is available on the treatment of AA-AMILZIDE overdosage and no specific antidote is available. Treatment is symptomatic and supportive. Therapy with AA-AMILZIDE should be discontinued and the patient observed closely. Suggested measures include induction of emesis and/or gastric lavage.

It is not known whether the drug is dialyzable.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

| Route of Administration | Dosage Form / Strength/Composition | Non-medicinal Ingredients |
|-------------------------|---|--|
| oral | tablet 5 mg / 50 mg contains 5 mg of amiloride hydrochloride and 50 mg of hydrochlorothiazide. | colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium bicarbonate and sunset yellow aluminium lake 40 %. |

AA-AMILZIDE Tablets, containing 5 mg amiloride hydrochloride and 50 mg hydrochlorothiazide, are peach-coloured, diamond-shaped, biconvex tablets. Scored and engraved “APO” over “5/50”. Available in bottles of 100.

7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

Carcinogenesis and Mutagenesis

Non-melanoma skin cancer: An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin] after hydrochlorothiazide therapy was reported in some epidemiological studies. The risk may be higher with increasing cumulative use (see [8.5 Post Market Adverse Drug Reactions](#)). The photosensitizing action of hydrochlorothiazide may be a possible mechanism for NMSC (see [16 NON-CLINICAL TOXICOLOGY, Carcinogenicity, Hydrochlorothiazide](#)).

Patients taking hydrochlorothiazide should be informed of the potential risk of NMSC. They should be advised to regularly check their skin for new lesions as well as changes to existing ones, and to promptly report any suspicious skin lesions. Patients should also be advised to limit exposure to sunlight, to avoid the use of indoor tanning equipment, and to use adequate protection (e.g. a broad spectrum sunscreen with a SPF of 30 or higher, clothing, and a hat) when exposed to sunlight or UV light to minimize the risk of skin cancer. Alternatives to hydrochlorothiazide may be considered for patients who are at a particularly high risk for NMSC (e.g., light coloured skin, known personal or family history of skin cancer, ongoing immunosuppressive therapy, etc.) (See [8.5 Post Market Adverse Drug Reactions](#)).

Driving and Operating Machinery

| The effect of AA-AMILZIDE on ability to drive and use machines has not been studied.

However, when driving or operating machinery it should be taken into account that with antihypertensive therapy, occasionally dizziness or drowsiness may occur. See [8 ADVERSE REACTIONS](#).

Endocrine and Metabolism

Hyperkalemia (See [3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Hyperkalemia](#)): When abnormal, the ECG in hyperkalemia is characterized primarily by tall, peaked T waves or elevations from previous tracings. There may also be lowering of the R wave and increased depth of the S wave, widening and even disappearance of the P wave, progressive widening of the QRS complex, prolongation of the PR interval, and ST depression.

If the serum potassium level exceeds 6.5 mEq per liter, active measures should be taken to reduce it. Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. If needed, a cation exchange resin such as sodium polystyrene sulfonate may be given orally or by enema. Patients with persistent hyperkalemia may require dialysis.

Electrolyte Imbalance and BUN Increases: Hyponatremia and hypochloremia may occur during the use of AA-AMILZIDE. Hypokalemia may also occur although the incidence is less than with thiazides alone. Any chloride deficit is usually mild and may be corrected by the use of ammonium chloride (except in patients with hepatic disease) and largely prevented by a near normal salt intake. Increases in BUN levels have been reported and have usually accompanied vigorous fluid elimination, especially when diuretic combinations were used in seriously ill patients, such as those who have hepatic cirrhosis with ascites and metabolic alkalosis, or those with resistant edema. Therefore, careful monitoring of serum electrolytes and BUN levels is important when using AA-AMILZIDE.

Diabetes Mellitus: In diabetic patients, hyperkalemia has been commonly reported with the use of amiloride hydrochloride, particularly if they have chronic renal disease or pre-renal azotemia. Some deaths occurred in this last group of patients. Therefore, if therapy with amiloride hydrochloride is considered essential, the drug should be used with caution in diabetic or suspected diabetic patients and only after first determining the status of renal function.

Careful monitoring of serum potassium levels is required throughout the therapy.

One patient with poorly controlled diabetes mellitus who became severely hyperkalemic while on amiloride hydrochloride died following two repeated intravenous glucose tolerance tests.

In diabetic patients, insulin requirements may be increased, decreased or unchanged due to the hydrochlorothiazide component. Diabetes mellitus which has been latent may become

manifest during administration of thiazide diuretics.

Other Precautions: Thiazides may decrease serum PBI levels without signs of thyroid disturbance.

Calcium excretion is decreased by hydrochlorothiazide and magnesium excretion is increased.

Pathological changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed in a few patients on prolonged thiazide therapy. The common complications of hyperparathyroidism such as renal lithiasis, bone resorption and peptic ulceration have not been seen.

Hyperuricemia may occur or gout may be precipitated.

Hematologic

Patients should be observed regularly for the possible occurrence of idiosyncratic reactions, or blood dyscrasias.

Hepatic/Biliary/Pancreatic

Effects Related to Diuresis in Cirrhotic Patients: Patients with hepatic cirrhosis and ascites are intolerant of acute shifts in electrolyte balance and often have pre-existing hypokalemia as a result of associated secondary hyperaldosteronism. When oral diuretic therapy is used, these patients should be carefully monitored and diuresis should be gradual.

Hepatic encephalopathy, manifested by tremors, confusion, and coma, has been reported in association with amiloride hydrochloride therapy.

In cirrhotic patients receiving amiloride hydrochloride alone, jaundice associated with the underlying disease process has deepened in a few instances, but the relationship to the drug is uncertain.

Patients should be observed regularly for the possible occurrence of liver dysfunction.

Immune

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported with the thiazides.

Ophthalmologic

Choroidal effusion, Acute Myopia and Secondary Angle-Closure Glaucoma:

Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in choroidal effusion, acute transient myopia and/or secondary acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity, blurred vision or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss.

The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulphonamide or penicillin allergy.

Peri-Operative Considerations

The antihypertensive effect of the drug may be enhanced in the post-sympathectomy patient.

Renal

Impaired Renal Function: Patients with impaired renal function other than those listed under section [2 CONTRAINDICATIONS](#) and who have BUN levels over 30 mg per 100 mL, serum creatinine levels over 1.5 mg per 100 mL, or blood urea values over 60 mg per 100 mL should not receive the drug without careful, frequent monitoring of serum electrolytes, creatinine and BUN levels. Potassium retention associated with the use of AA-AMILZIDE is accentuated in the presence of renal impairment and may result in the rapid development of hyperkalemia.

Prolongation of amiloride hydrochloride excretion was observed in patients with renal impairment.

In patients with impaired renal function azotemia may be precipitated or increased by hydrochlorothiazide. Careful monitoring of such patients is therefore necessary.

Reproductive Health: Female and Male Potential

- **Fertility**
Reproduction studies in rats showed no evidence of impaired fertility (See [16 NON-CLINICAL TOXICITY, Reproductive and Developmental Toxicology](#)).
- **Teratogenic Risk**
Teratologic studies with amiloride hydrochloride in rabbits and mice revealed no evidence of harm to the fetus. At approximately 5 or more times the expected maximum daily dose for humans, some toxicity was seen in adult rats and rabbits and a decrease in

rat pup growth and survival occurred (See [16 NON-CLINICAL TOXICITY, Reproductive and Developmental Toxicology](#)).

Respiratory

Acute Respiratory Distress: Severe cases of acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary oedema typically develops within minutes to hours after hydrochlorothiazide intake. At the onset, symptoms can include dyspnoea, fever, pulmonary deterioration and hypotension. If diagnosis of ARDS is suspected, AA-AMILZIDE should be withdrawn and appropriate treatment given. AA-AMILZIDE should not be administered to patients who previously experienced ARDS following intake of hydrochlorothiazide intake.

Metabolic or Respiratory Acidosis: Antikaliuretic therapy should be instituted only with caution in patients in whom respiratory or metabolic acidosis may occur, such as patients with cardiopulmonary disease or diabetes. If AA-AMILZIDE is given to these patients, frequent monitoring of acid-base balance is necessary. Shifts in acid-base balance alter the ratio of extracellular/intracellular potassium, and the development of acidosis may be associated with rapid increases in serum potassium levels.

Sensitivity/Resistance

Sensitivity reactions to thiazides may occur in patients with or without a history of allergy or bronchial asthma.

Skin

Photosensitivity: Photosensitivity reactions have been reported with the use of thiazide diuretics.

7.1 Special Populations

7.1.1 Pregnant Women

Because clinical experience is limited, AA-AMILZIDE is not recommended for use during pregnancy.

In rats, a trace of drug crossed the placental barrier.

Thiazides cross the placental barrier and appear in the cord blood. Therefore, the use of AA-AMILZIDE when pregnancy is present or suspected requires that the benefits of the drug be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia and possibly other side effects that have occurred in the adult.

7.1.2 Breast-feeding

It is not known whether amiloride hydrochloride is excreted in human milk. In rats, secretion of amiloride hydrochloride in milk has been demonstrated. Thiazides appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, if the use of AA-AMILZIDE is deemed essential, the patient should stop nursing.

7.1.3 Pediatrics

Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety for use of amiloride hydrochloride in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4 Geriatrics

Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (See [3](#) [SERIOUS WARNINGS AND PRECAUTIONS BOX, Hyperkalemia](#)).

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

While rare, the most serious adverse effect of AA-AMILZIDE (amiloride hydrochloride and hydrochlorothiazide) is symptomatic hyperkalemia. Other metabolic changes that occur are asymptomatic hyperkalemia, hypokalemia and hypochloremia.

8.2 Clinical Trials Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

The following incidence of other adverse reactions was reported in patients treated with a combination of hydrochlorothiazide and amiloride hydrochloride.

Table 2: Adverse reactions reported in patients treated with a combination of hydrochlorothiazide and amiloride hydrochloride

| | Common Incidence ≥3% | Common Incidence >1%- <3% | Uncommon Incidence ≤1% |
|---|---------------------------------------|---|---|
| Cardiac disorders (In 4.3% of patients) | | Arrhythmia | Tachycardia Angina pectoris |
| Eye disorders (In 13.9% of patients) | | | Visual disturbance |
| Gastrointestinal disorders (In 7.1% of patients) | Nausea (3.7%) | Diarrhea Gastrointestinal pain. Abdominal pain. | Constipation GI bleeding GI disturbance Appetite changes Abdominal fullness Hiccups Vomiting Flatulence Bad taste |
| General disorders and administration site conditions | Weakness (4.0%) (13.9% of patients) | Fatigue/tiredness (In 2.6% of patients) | Malaise (In 2.6% of patients) Chest pain (In 3.7% of patients) Thirst (In 7.1% of patients) |
| Injury poisoning and procedural complications (In 4.3% of patients) | | | Digitalis Toxicity |
| Metabolism and Nutrition Disorders (In 0.9% of patients) | Anorexia (3.7%) (In 7.1% of patients) | | Gout Dehydration |
| Musculoskeletal and connective tissue disorders (In 3.7% of patients) | | Leg ache | Muscle cramps/spasm Joint pain Back pain |
| Nervous system disorders (In 13.9% of patients) | Headache (7.8%) Dizziness (6.1%) | | Paresthesia Numbness Stupor Vertigo |

| | Common Incidence ≥3% | Common Incidence >1%- <3% | Uncommon Incidence ≤1% |
|---|-----------------------------|--|---|
| Psychiatric disorders (In 13.9% of patients) | | | Insomnia Nervousness Depression Sleepiness Mental confusion |
| Renal and Urinary disorders (In 1.7% of patients) | | | Nocturia Dysuria Incontinence |
| Reproductive system and breast disorders (In 1.7% of patients) | | | Impotence |
| Respiratory, thoracic and mediastinal disorders (In 2.6% of patients) | | Dyspnea | Nasal congestion |
| Skin and subcutaneous tissue disorders (In 5.2% of patients) | Rash (3.4%) | Pruritus | Flushing |
| Vascular disorders (In 4.3% of patients) | | | Orthostatic hypotension |

Other adverse reactions that have been reported with the individual components are listed below:

Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, purpura, thrombocytopenia, neutropenia.

Eye disorders: Transient blurred vision, xanthopsia.

Immune system disorders: Anaphylactic reactions.

Gastrointestinal disorders: Activation of pre-existing peptic ulcer, cramping, gastric irritation, pancreatitis, dry mouth, sialadenitis.

General disorders and administration site conditions: Fever.

Hepatobiliary disorders: Abnormal liver function, jaundice (intrahepatic cholestatic jaundice).

Metabolism and nutrition disorders: Hyperglycemia, hyperuricemia.

Psychiatric disorders: Restlessness.

Renal and urinary disorders: Glycosuria.

Respiratory, thoracic and mediastinal disorders: Respiratory distress including pneumonitis.

Skin and subcutaneous tissue disorders: Photosensitivity, urticaria.

Vascular disorders: Necrotizing angiitis (vasculitis, cutaneous vasculitis).

8.5 Post-Market Adverse Reactions

Eye disorder

Choroidal effusion, acute myopia, acute angle-closure glaucoma (unknown frequency)

Non-melanoma skin cancer

Some pharmacoepidemiological studies have suggested a higher risk of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) of the skin with increasing use of hydrochlorothiazide. A systematic review and meta-analysis undertaken by Health Canada suggested that, with important uncertainty, the use of hydrochlorothiazide for several years (>3 years) could lead to:

- 122 additional cases (95% CI, from 112 to 133 additional cases) of SCC per 1000 treated patients compared with non-use of hydrochlorothiazide (meta-analysis of 3 observational studies);
- 31 additional cases (95% CI, from 24 to 37 additional cases) of BCC per 1000 treated patients compared with non-use of hydrochlorothiazide (meta-analysis of 2 observational studies).

Respiratory

Very rare: Acute respiratory distress syndrome.

9 DRUG INTERACTIONS

9.1 Serious Drug Interactions

Serious Drug Interactions

- **Digoxin:** Thiazide-induced electrolyte disturbances, i.e. hypokalemia, hypomagnesemia,

increase the risk of digoxin toxicity, which may lead to fatal arrhythmic events. (See [9.4 Drug-Drug Interactions, Digoxin](#)).

- **Nonsteroidal anti-inflammatory drugs (NSAID):** NSAID-related retention of sodium and water antagonises the diuretic and antihypertensive effects of thiazides.

NSAID-induced inhibition of renal prostaglandins leading to decreases of renal blood flow, along with thiazide-induced decreases in GFR may lead to acute renal failure. Patients with heart failure may be at particular risk (See [9.4 Drug-Drug-Interactions, Nonsteroidal anti-inflammatory drugs \(NSAID\)](#)).

- **Antikaliuretic agents or Potassium Salts:** Other antikaliuretic agents and potassium supplements are contraindicated in patients receiving AA-AMILZIDE. See [2 CONTRINDICATIONS](#).

9.3 Drug-Behavioural Interactions

Consuming alcohol may modify the effect of this product. Avoid alcohol consumption during treatment.

9.4 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 3 - Established or Potential Drug-Drug Interactions with Amiloride Hydrochloride

| Proper/ Common name | Source of Evidence | Effect | Clinical comment |
|---|-----------------------|---|--|
| Angiotensin- Converting Enzyme Inhibitors, Angiotensin II receptor antagonist | T | When amiloride hydrochloride is administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, the risk of hyperkalemia may be increased. | If concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. |

| Proper/ Common name | Source of Evidence | Effect | Clinical comment |
|--|-------------------------------|--|--|
| Cyclosporine or Tacrolimus, | T | When amiloride hydrochloride is administered concomitantly with cyclosporine or tacrolimus, the risk of hyperkalemia may be increased. | If concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. |
| Lithium | T | Lithium should generally not be given with diuretics because they reduce the renal clearance of lithium and add a high risk of lithium toxicity. | |
| Nonsteroidal anti-inflammatory drugs (NSAID) | CT | In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic and hypertensive effects of diuretics. Concomitant administration of non-steroidal anti-inflammatory drugs (NSAIDs) and potassium-sparing agents, including amiloride hydrochloride, may cause hyperkalemia and renal failure, particularly in elderly patients. | When amiloride hydrochloride is used concomitantly with NSAIDs, renal function and serum potassium levels should be carefully monitored. |

Table 4 - Established or Potential Drug-Drug Interactions with Hydrochlorothiazide

| Proper/Common name | Source of Evidence | Effect | Clinical comment |
|-------------------------------------|---------------------------|---|--|
| Alcohol, barbiturates, or narcotics | C | Potential of orthostatic hypotension may occur. | Avoid alcohol, barbiturates or narcotics, especially with initiation of therapy. |

| Proper/Common name | Source of Evidence | Effect | Clinical comment |
|---|---------------------------|---|---|
| Amphotericin B | T | Amphotericin B increases the risk of hypokalemia induced by thiazide diuretics. | Monitor serum potassium level. |
| Antidiabetic agents (e.g. insulin and oral hypoglycemic agents) | CT | Thiazide-induced hyperglycemia may compromise blood sugar control. Depletion of serum potassium augments glucose intolerance. | Monitor glycemic control, supplement potassium if necessary, to maintain appropriate serum potassium levels, and adjust diabetes medications as required. |
| Antihypertensive drugs | CT | Hydrochlorothiazide may potentiate the action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACEI, ARB, and direct renin inhibitors). | |
| Antineoplastic drugs, including cyclophosphamide and methotrexate | C | Concomitant use of thiazide diuretics may reduce renal excretion of cytotoxic agents and enhance their myelosuppressive effects | Hematological status should be closely monitored in patients receiving this combination. Dose adjustment of cytotoxic agents may be required. |
| Bile acid sequestrants, e.g. cholestyramine | CT | Bile acid sequestrants bind thiazide diuretics in the gut and impair gastrointestinal absorption by 43-85%. Administration of thiazide 4 hours after a bile acid sequestrant reduced absorption of hydrochlorothiazide by 30-35%. | Give thiazide 2-4 hours before or 6 hours after the bile acid sequestrant. Maintain a consistent sequence of administration. Monitor blood pressure, and increase dose of thiazide, if necessary. |

| Proper/Common name | Source of Evidence | Effect | Clinical comment |
|---|---------------------------|--|--|
| Calcium and vitamin D supplements | C | Thiazides decrease renal excretion of calcium and increase calcium release from bone | Monitor serum calcium, especially with concomitant use of high doses of calcium supplements. Dose reduction or withdrawal of calcium and/or vitamin D supplements may be necessary. |
| Carbamazepine | C | Carbamazepine may cause clinically significant hyponatremia. Concomitant use with thiazide diuretics may potentiate hyponatremia. | Monitor serum sodium levels. Use with caution. |
| Corticosteroids, and adrenocorticotrophic hormone (ACTH) | T | Intensified electrolyte depletion, particularly hypokalemia, may occur. | Monitor serum potassium, and adjust medications, as required. |
| Digoxin | CT | Thiazide-induced electrolyte disturbances, i.e. hypokalemia, hypomagnesemia, increase the risk of digoxin toxicity, which may lead to fatal arrhythmic events. | Concomitant administration of hydrochlorothiazide and digoxin requires caution. Monitor electrolytes and digoxin levels closely. Supplement potassium or adjust doses of digoxin or thiazide, as required. |
| Drugs that alter GI motility, i.e., anticholinergic agents, such as atropine and prokinetic agents, such as metoclopramide, domperidone | CT, T | Bioavailability of thiazide diuretics may be increased by anticholinergic agents due to a decrease in gastrointestinal motility and gastric emptying. Conversely, prokinetic drugs may decrease the bioavailability of thiazide diuretics. | Dose adjustment of thiazide may be required. |

| Proper/Common name | Source of Evidence | Effect | Clinical comment |
|---|---------------------------|---|--|
| Gout medications (allopurinol, uricosurics, xanthine oxidase inhibitors) | T, RCS | Thiazide-induced hyperuricemia may compromise control of gout by allopurinol and probenecid. The co-administration of hydrochlorothiazide and allopurinol may increase the incidence of hypersensitivity reactions to allopurinol. | Dosage adjustment of gout medications may be required. |
| Lithium | CT | Thiazide diuretics reduce the renal clearance of lithium and add a high risk of lithium toxicity. | Concomitant use of thiazide diuretics with lithium is generally not recommended. If such use is deemed necessary, reduce lithium dose by 50% and monitor lithium levels closely. |
| Nonsteroidal anti-inflammatory drugs (NSAID) | CT | NSAID-related retention of sodium and water antagonises the diuretic and antihypertensive effects of thiazides. NSAID-induced inhibition of renal prostaglandins leading to decreases of renal blood flow, along with thiazide-induced decreases in GFR may lead to acute renal failure. Patients with heart failure may be at particular risk. | If combination use is necessary, monitor renal function, serum potassium, and blood pressure closely. Dose adjustments may be required. |
| Selective serotonin reuptake inhibitors (SSRIs, e.g., citalopram, escitalopram, sertraline) | T, C | Concomitant use with thiazide diuretics may potentiate hyponatremia. | Monitor serum sodium levels. Use with caution. |

| Proper/Common name | Source of Evidence | Effect | Clinical comment |
|--|--------------------|---|---|
| Skeletal muscle relaxants of the curare family, e.g., tubocurare | C | Thiazide drugs may increase the responsiveness of some skeletal muscle relaxants, such as curare derivatives. | |
| Topiramate | CT | Additive hypokalemia. Possible thiazide-induced increase in topiramate serum concentrations. | Monitor serum potassium and topiramate levels. Use potassium supplements, or adjust topiramate dose as necessary. |

Legend: C = Case Study; RCS = Retrospective Cohort Study; CT = Clinical Trial; T = Theoretical

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

AA-AMILZIDE is a diuretic/antihypertensive combining the potent natriuretic action of hydrochlorothiazide with the potassium-conserving property of amiloride hydrochloride. The mild diuretic and antihypertensive actions of amiloride hydrochloride are additive to the natriuretic, diuretic and antihypertensive activity of the thiazide while minimizing the loss of potassium and lessening the likelihood of acid-base imbalance. The onset of the diuretic action of AA-AMILZIDE is within 1 to 2 hours and this action appears to be sustained for approximately 24 hours.

Hydrochlorothiazide

Hydrochlorothiazide is a diuretic and antihypertensive agent. It affects the renal tubular mechanism of electrolyte reabsorption. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts and may cause a simultaneous, usually

minimal, loss of bicarbonate. Natriuresis is usually accompanied by some loss of potassium.

The mechanism of the antihypertensive effect of thiazides may be related to the excretion and redistribution of body sodium. Hydrochlorothiazide usually does not decrease normal blood pressure.

Amiloride Hydrochloride

Amiloride hydrochloride is an antikaliuretic drug with mild natriuretic diuretic and antihypertensive activity. These activities may be additive to the effects of thiazides or other saluretic-diuretic agents. The principal use of amiloride hydrochloride is to conserve potassium in selected patients receiving kaliuretic-diuretic agents. The action is not related to the level of aldosterone excretion. Amiloride hydrochloride is not an aldosterone antagonist. The drug acts directly on the distal portion of the nephron. Amiloride hydrochloride causes an increase in sodium excretion and a decrease in potassium and hydrogen ion excretion. Chloride excretion may remain unchanged or increase slowly with continued therapy.

10.2 Pharmacodynamics

Hydrochlorothiazide

Hydrochlorothiazide has diuretic and antihypertensive activities. This compound increases the excretion of sodium and chloride in approximately equivalent amounts and causes a simultaneous, usually minimal loss of bicarbonate. The excretion of ammonia is reduced slightly by hydrochlorothiazide and the blood ammonia concentration may be increased. The excretion of potassium is increased slightly. Calcium excretion is decreased by hydrochlorothiazide and magnesium excretion is increased.

Hydrochlorothiazide is eliminated rapidly by the kidney. Its rate of elimination is decreased somewhat by the co-administration of probenecid without, however, an accompanying reduction in diuresis.

Amiloride hydrochloride

Amiloride hydrochloride is chemically unrelated to other known antikaliuretic or diuretic agents. It is a salt of a moderately strong base (pKa 8.7).

In rats and dogs, amiloride hydrochloride in an oral dose of 0.1 mg/kg or less increases the excretion of sodium and to a lesser extent, of chloride but does not increase the excretion of potassium. A potassium-retaining effect is seen in experimental animals, especially under conditions of high potassium excretion, as upon loading with potassium chloride, after pre-treatment with acetazolamide or thiazides, or in deoxycorticosterone-treated adrenalectomized rats. The natriuresis is accompanied by an increase in urinary pH,

reflecting a decrease in hydrogen ion excretion. Following oral administration to dogs, amiloride hydrochloride increases the rate of sodium excretion less than do the more potent agents, but the moderate effect on sodium excretion has an extended duration. Natriuresis increases only moderately as the oral dose is increased from 0.25 to 4.0 mg/kg; this activity persists beyond 6 hours.

An increase in sodium excretion is produced when amiloride hydrochloride is given together with chlorothiazide, hydrochlorothiazide, or acetazolamide to rats. Amiloride hydrochloride antagonizes the kaliuretic effect of the other diuretic. Oral doses of amiloride hydrochloride (0.1 to 0.5 mg/kg) increase the excretion of sodium and decrease that of potassium in dogs given ethacrynic acid (1.0 mg/kg) or hydrochlorothiazide (0.5 mg/kg) orally.

Amiloride hydrochloride increases the Na^+/K^+ excretion ratio in adrenalectomized rats. In adrenalectomized rats treated with aldosterone, deoxycorticosterone, or hydrocortisone, amiloride hydrochloride not only reverses the steroid-induced sodium retention, but increases the Na^+/K^+ excretion ratio substantially above that of untreated adrenalectomized rats.

Stop-flow studies in dogs indicate that amiloride hydrochloride inhibits tubular secretion of potassium and reabsorption of sodium in the distal portion of the nephron. In renal clearance studies, 1.0 mg/kg intravenously did not affect glomerular filtration rate, effective renal plasma flow, or glucose reabsorption. An enzymatic basis for the renal action of amiloride hydrochloride has not been elucidated. It is not an inhibitor of carbonic anhydrase.

Amiloride hydrochloride given parenterally (2.5 to 5.0 mg/kg) to anesthetized dogs produces profound reduction of blood pressure and produces changes in the electrocardiogram. The effects which are coincident with the release of histamine into plasma, are not seen if the compound is injected slowly or if lower doses are given. A slight increase in gastric secretion and intestinal motility occurred after oral administration to dogs of 0.5 to 2.0 mg/kg. Pre-treatment of several days with amiloride hydrochloride in a dose of 5 mg/kg/day by mouth does not alter the response of dogs to ouabain.

10.3 Pharmacokinetics

Absorption

Hydrochlorothiazide: The onset of the diuretic action of hydrochlorothiazide occurs in 2 hours and the peak action in about 4 hours. Diuretic activity lasts about 6 to 12 hours.

Amiloride hydrochloride: Approximately 50% of an oral dose is absorbed. Amiloride hydrochloride usually begins to act within 2 hours after an oral dose. Its effect on electrolyte excretion reaches a peak between 6 and 10 hours and lasts about 24 hours.

Distribution

Amiloride hydrochloride: Peak plasma levels are obtained in 3 to 4 hours and plasma half-life varies from 6 to 9 hours.

Metabolism

Amiloride hydrochloride: Amiloride hydrochloride is not metabolized by the liver.

Elimination

Hydrochlorothiazide: Hydrochlorothiazide is eliminated rapidly by the kidney.

Amiloride hydrochloride: About 50% of a 20 mg dose of amiloride hydrochloride is excreted unchanged in the urine and 40% is excreted in the stool within 72 hours. In clinical studies amiloride hydrochloride was found to have little effect on glomerular filtration rate or renal blood flow.

Special Populations and Conditions

- **Pediatrics:** The safety and efficacy of amiloride hydrochloride and hydrochlorothiazide in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use (See [7.1.3 Pediatrics](#)).
- **Geriatrics:** The clinical trial data on which the indication was originally authorised is not available.
- **Sex:** The clinical trial data on which the indication was originally authorised is not available.
- **Pregnancy and Breast-feeding:** Amiloride hydrochloride and hydrochlorothiazide is not recommended for use during pregnancy and breastfeeding (See [7.1.1 Pregnant women](#) and [7.1.2 Breast-feeding](#)).
- **Genetic Polymorphism:** The clinical trial data on which the indication was originally authorised is not available.
- **Ethnic Origin:** The clinical trial data on which the indication was originally authorised is not available.
- **Hepatic Insufficiency:** Patients with hepatic cirrhosis and ascites should be carefully monitored (See [7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic](#)).
- **Renal Insufficiency:** Careful monitoring is necessary in patients with impaired renal function while using amiloride hydrochloride and hydrochlorothiazide (See [7 WARNINGS AND PRECAUTIONS, Renal](#)).
- **Obesity:** The clinical trial data on which the indication was originally authorized is not available.

11 STORAGE, STABILITY AND DISPOSAL

Store at room temperature (15°C to 30°C).

AA-AMILZIDE should never be disposed of in household trash. Disposal via a pharmacy take back program is recommended.

12 SPECIAL HANDLING INSTRUCTIONS

None.

PART II: SCIENTIFIC INFORMATION


13 PHARMACEUTICAL INFORMATION

Drug Substances

Hydrochlorothiazide

| | |
|---------------------------------------|--|
| Proper name: | Hydrochlorothiazide |
| Chemical name: | 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. |
| Molecular formula and molecular mass: | C ₇ H ₈ ClN ₃ O ₄ S ₂ and 297.72 g/mol. |

Structural formula:




| | |
|----------------------------|--|
| Physicochemical properties | Hydrochlorothiazide is a white or practically white compound with low solubility in water, but readily soluble in dilute aqueous sodium hydroxide. |
|----------------------------|--|

Amiloride hydrochloride

| | |
|---------------------------------------|--|
| Proper name: | Amiloride hydrochloride |
| Chemical name: | 3,5-Diamino-N-(aminoiminomethyl)- 6-chloropyrazinecarboxamide hydrochloride. |
| Molecular formula and molecular mass: | C ₆ H ₈ ClN ₇ O.HCl and 266.1 g/mol |

Structural formula:



• HCl

| | |
|-----------------------------|---|
| Physicochemical properties: | Amiloride hydrochloride is a yellow to greenish yellow, odourless or practically odourless, crystalline compound, soluble in water. |
|-----------------------------|---|

14 CLINICAL TRIALS

14.2 Comparative Bioavailability Studies

Bioavailability studies were performed using normal human volunteers. The rate and extent of absorption after a single oral dose of 5 mg amiloride and 50 mg hydrochlorothiazide in the form of AA-AMILZIDE 5-50 mg and MODURET 5-50 mg was measured and compared. The results can be summarized as follows:

| Amiloride HCl | MODURET (SD*) | AA-AMILZIDE (SD) |
|--------------------------------|----------------------|-------------------------|
| AUC ₀₋₂₄ (ng-hr/mL) | 62.5 (21.0) | 66.8 (18.4) |
| C _{max} (ng/mL) | 6.0 (2.2) | 6.7 (2.4) |
| T _{max} (hrs) | 3.8 (0.6) | 3.3 (0.8) |
| t _{1/2} (hrs) | 8.2 (2.5) | 9.6 (3.8) |
| | | |
| Hydrochlorothiazide | | |
| AUC ₀₋₂₄ (ng-hr/mL) | 1603 (414) | 1654 (426) |
| C _{max} (ng/mL) | 235 (73) | 242 (60) |
| T _{max} (hrs) | 2.3 (1.0) | 2.4 (0.8) |
| t _{1/2} (hrs) | 9.1 (3.3) | 10.0 (5.6) |
| *SD = Standard Deviation | | |

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

Acute Toxicity:

| Oral LD₅₀ (mg/kg) | | | |
|-------------------------------------|------------------------------------|----------------------------|---|
| SPECIES | AMILORIDE HYDROCHLORIDE | HYDROCHLOROTHIAZIDE | AMILORIDE HYDROCHLORIDE / HYDROCHLOROTHIAZIDE 5:50 |
| MICE | 56 | >10,000 | 189 |
| RATS | 36-85 | >10,000 | 422 (FEMALES) 377 (MALES) |

Acute oral studies of fixed combinations in the mouse and rat showed that the toxicity was based primarily on the amiloride content.

Subacute and Chronic Toxicity:

Amiloride Hydrochloride and Hydrochlorothiazide

Twelve-week and 25-week oral studies of the combination in the rat indicated the toxicity expected from the individual ingredients (fluid loss at high doses and hyperplasia of the adrenal zona glomerulosa). No evidence of drug interaction was seen. The high dose in the 12-week study (10 mg/kg of amiloride hydrochloride with 500 mg/kg of hydrochlorothiazide) was not well tolerated; 11 of 30 animals died.

The toxicity was related to effects on serum electrolytes.

In the dog, effects observed included dry nose and gums, diuresis, natriuresis, chloruresis, antikaluresis and hyperplasia of the adrenal zona glomerulosa.

Electrocardiographic changes suggestive of potassium retention were seen at high dose levels. A dose of 5/50 mg/kg resulted in deaths from electrolyte imbalance. A dose of 2.5/25 mg/kg increased to 4.0/40 mg/kg/day was tolerated for six months.

Amiloride Hydrochloride

MODERATE TO MARKED HYPERKALEMIA DEVELOPED AT HIGHER DOSES IN ALL SPECIES. SERUM SODIUM AND CHLORIDE WERE DECREASED.

Rats were given amiloride at oral daily doses of 2.5, 5, 10 to 15 mg/kg/day for up to 18 months. Doses of 10 to 15 mg/kg/day caused a high incidence of deaths, probably due to severe electrolyte imbalance.

In a 6-week study, GI ulcerations were observed in 1 of 4 dogs at 2.5 mg/kg and 2 of 4 dogs at 10 mg/kg.

Rats received amiloride hydrochloride by oral route at doses of 0, 2.5, 5.0, and 10 to 15 mg/kg for up to 80 weeks. Inhibition of weight gain occurred in male rats. Drug induced changes included alterations in urinary and serum electrolytes (which resulted in severe symptoms in the high dose group), reversible hyperplasia of the zona glomerulosa at all doses and renal tubular dilation at 10 mg/kg/day.

Dogs treated with oral doses of 0, 2, 4 and 8 mg/kg/day (base) for one year showed changes in body weight, water intake and serum electrolytes. Positive fecal occult blood occurred at a slightly greater incidence in treated animals but no evidence of gastrointestinal ulceration was seen. Dose-dependent hyperplasia of the zona glomerulosa of the adrenal was observed in all treated dogs.

Monkeys were given amiloride at oral doses up to 12 mg/kg/day, 5 days/week, for 49 weeks. Excitability and irritability, electrolyte imbalance and increased adrenal weights occurred at 12 mg/kg/day. It was reported that urinary excretion of aldosterone was increased in high dose animals.

Carcinogenicity:

Hydrochlorothiazide

According to the experimental data available, hydrochlorothiazide revealed inconsistent evidence of carcinogenic activity in rats and mice, with conflicting evidence of hepatic adenoma in male mice at the highest dose and adrenal pheochromocytoma in one rat study but not in another. Current evidence is inadequate to draw a clear conclusion for a carcinogenic effect of hydrochlorothiazide in animals.

Amiloride hydrochloride

No tumorigenic effect was observed when amiloride hydrochloride was administered for 92 weeks to mice at doses of up to 10 mg/kg/day and for 104 weeks to rats at doses of up to 8 mg/kg/day.

Genotoxicity:

Hydrochlorothiazide

The mutagenic potential was assessed in a series of *in vitro* and *in vivo* test systems. While some positive results were obtained *in vitro*, all *in vivo* studies provided negative results. Hydrochlorothiazide enhanced the UVA-induced formation of pyrimidine dimers *in vitro* and in the skin of mice following oral treatment. It is therefore concluded that although there is no relevant mutagenic potential *in vivo*, hydrochlorothiazide could enhance the genotoxic effects of UVA light. This mechanism of photosensitization could be associated with a higher risk for non-melanoma skin cancer.

Reproductive and Developmental Toxicology:

Amiloride hydrochloride and hydrochlorothiazide combinations were administered orally to pregnant mice at dosage levels of 1/5, 5/25 and 5/50 mg/kg/day (12.5 times the expected maximum daily dose for humans) and to pregnant rabbits at dosage levels of 1.0/2.5, 1/5 and 4/20 mg/kg/day (10/20 times the expected maximum daily dose for humans). In a second study in pregnant rabbits, amiloride hydrochloride and hydrochlorothiazide was administered at dosage levels of 0.5/5, 1/10 and 2/20 mg/kg/day (5 times the expected maximum daily dose for humans). No teratogenic embryotoxic, fetotoxic, or maternotoxic effects attributable to treatment were observed in either species.

No effect on reproductive performance or fertility in albino rats given 2, 4, or 8 mg/kg/day

amiloride base orally was noted. Growth rate and food consumption were reduced at the highest dose. Doses of 4 and 8 mg/kg/day were administered without effect during late gestation and growth. The high dose adversely affected pup survival and growth.

Special Toxicology:

Special Studies Relative to Adrenal Zona

Glomerulosa, Hyperplasia and Diabetes: Amiloride hydrochloride produced a dose-dependent hyperplasia of the zona glomerulosa of the adrenal cortex in rats and dogs, however, no adrenal hyperplasia occurred in monkeys, although adrenal weights were increased. In rats, reversibility of the hyperplasia was demonstrated after the drug was given for 58 weeks and the animals were observed for an additional 22 weeks. Hyperplasia has been shown to disappear in 19 to 30 days after cessation of treatment and the adrenals were normal within 30 to 58 days. The hyperplasia can be reduced by substitution of physiologic saline for drinking water. Hyperplasia of the adrenal zona glomerulosa occurred in maternal mice but not in the offspring in a teratogenic study. The hyperplasia is considered to be induced by alteration of serum electrolytes and/or inhibition of aldosterone activity.

No effect on carbohydrate metabolism was observed when the toxicity of amiloride hydrochloride was studied in obese diabetic Zucker rats and normal-thin rats. Amiloride hydrochloride had no adverse effect on glucose tolerance in acute experiments in rats or in a chronic study in dogs.

Amiloride hydrochloride and Hydrochlorothiazide Combination

Rats were given 5/100, 10/500 mg/kg amiloride hydrochloride and hydrochlorothiazide 5 days/week for 25 weeks. Animals at the high dose experienced high mortality rates. Dogs were given 1/5, 4/40 mg/kg amiloride hydrochloride and hydrochlorothiazide 5 to 7 days/week for 25 weeks and 5/50 mg/kg 7 days/week for 13 weeks. At higher doses the toxic effects in rats and dogs were adrenal zona glomerulosa hyperplasia, electrolyte imbalance, elevated BUN, ECG disturbances, and focal tubular fatty changes of the kidney.

17 SUPPORTING PRODUCT MONOGRAPHS

1. Moduret tablets, 50 mg. Product Monograph, Merck Sharp & Dohme Canada Ltd.; (JUN 11, 1982).

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **AA-AMILZIDE**

Amiloride Hydrochloride and Hydrochlorothiazide Tablets

Read this carefully before you start taking **AA-AMILZIDE** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **AA-AMILZIDE**.

Serious Warnings and Precautions

AA-AMILZIDE may cause high levels of potassium in your blood (hyperkalemia). If you are 65 years of age or older, diabetic, have liver disease, heart disease, kidney problems, are very ill, or are taking other diuretic medicines, you are more likely to develop hyperkalemia. Your healthcare professional may do blood tests to monitor the potassium levels in your blood. Talk to your healthcare professional right away if you have an irregular heartbeat, nausea or vomiting, chest pain, numbness or tingling in the hands, feet or lips, shortness of breath, or weakness or heaviness of the arms or legs.

What is AA-AMILZIDE used for?

AA-AMILZIDE is used to treat adults who have:

- scarring of the liver (liver cirrhosis) with fluid in the abdomen and swelling of the hands, ankles, or feet (edema).
- swelling of the hands, ankles, or feet caused by heart problems.
- high blood pressure (hypertension) and have low levels of potassium in their blood (hyperkalemia) or who need to maintain normal levels of potassium.

How does AA-AMILZIDE work?

AA-AMILZIDE contains a combination of 2 drugs, amiloride hydrochloride and hydrochlorothiazide:

- amiloride hydrochloride helps the body lose excess salt but keep a normal amount of potassium (an electrolyte) in the blood.
- hydrochlorothiazide is a diuretic or “water pill” that increases urination. It works by causing the kidneys to get rid of unneeded water and salt from the body into the urine. It also helps lower blood pressure.

This medicine does not cure high blood pressure. It helps to control it. Therefore, it is important to continue taking AA-AMILZIDE regularly even if you feel fine. Do not stop taking AA-AMILZIDE without talking to your healthcare professional.

What are the ingredients in AA-AMILZIDE?

Medicinal ingredients: amiloride hydrochloride and hydrochlorothiazide.

Non-medicinal ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium bicarbonate and sunset yellow aluminium lake 40 %.

AA-AMILZIDE comes in the following dosage forms:

Tablet; 5 mg / 50 mg.

Do not use AA-AMILZIDE if:

- you are allergic to amiloride hydrochloride or hydrochlorothiazide, or to any non-medicinal ingredient in AA-AMILZIDE.
- you are allergic to any sulfonamide-derived drugs (sulfa drugs); most of them have a medicinal ingredient that ends in “-MIDE”.
- you have difficulty urinating or produce no urine.
- you have high levels of potassium in your blood (hyperkalemia).
- you have kidney failure, severe or worsening kidney disease or problems with your kidneys because of diabetes (diabetic nephropathy).
- you are taking any form of potassium supplements.
- you are taking any other potassium sparing diuretics (a specific kind of “water pill” that makes your body keep potassium).
- you have one of the following rare hereditary diseases:
 - Galactose intolerance
 - Lapp lactase deficiency
 - Glucose-galactose malabsorption

Because lactose is a non-medicinal ingredient in AA-AMILZIDE.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take AA-AMILZIDE. Talk about any health conditions or problems you may have, including if you:

- are allergic to penicillin.
- have liver, heart or kidney disease.
- have high blood sugar or diabetes. AA-AMILZIDE may affect your blood sugar levels and accelerate the development of diabetes.
- have a disease involving both the lungs and heart (cardiopulmonary disease).

- had or plan to have a sympathectomy (a surgery to remove part of a nerve from your spinal cord).
- have lupus.
- have high levels of uric acid in the blood or have gout. AA-AMILZIDE may make a gout attack more likely.
- have a stomach (peptic) ulcer.
- are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.
- are 65 years of age or older.
- have had skin cancer or have a family history of skin cancer.
- have a greater chance of developing skin cancer because you have light-coloured skin, get sunburned easily, or are taking drugs to suppress your immune system.
- have had breathing or lung problems (including inflammation or fluid in the lungs) in the past following the use of medication containing hydrochlorothiazide.
- have problems with your thyroid or parathyroid glands.

Other warnings you should know about:

Risk of skin cancer:

- AA-AMILZIDE contains hydrochlorothiazide. Taking hydrochlorothiazide may increase your risk of developing non-melanoma skin cancer. The risk is higher if you have been taking AA-AMILZIDE for many years (more than 3) or at a high dose.
- While taking AA-AMILZIDE:
 - Make sure to regularly check your skin for any new lesions. Check areas that are most exposed to the sun, such as the face, ears, hands, shoulders, upper chest and back.
 - You may become more sensitive to the sun while taking AA-AMILZIDE. Limit your exposure to the sun and to indoor tanning. Always use sunscreen (SPF-30 or higher) and wear protective clothing when going outside.
 - Talk to your healthcare professional immediately if you get more sensitive to the sun or UV light or if you develop an unexpected skin lesion (such as a lump, bump, sore, or patch) while you are taking AA-AMILZIDE.

Sudden eye problems:

- AA-AMILZIDE contains hydrochlorothiazide. Taking hydrochlorothiazide can cause serious eye problems. These eye problems are related and can happen within hours to weeks of starting AA-AMILZIDE.
- These eye problems include:
 - **Choroidal effusion:** An abnormal buildup of liquid in your eye that may result in vision changes.
 - **Myopia:** Sudden nearsightedness or blurred vision.
 - **Glaucoma:** An increased pressure in your eyes, eye pain. Untreated, it may lead to permanent vision loss.
- If your vision changes, stop taking AA-AMILZIDE and get immediate medical help.

Driving and using machines: Before you perform tasks which may require special attention, wait until you know how you respond to AA-AMILZIDE. Dizziness, lightheadedness, or fainting can occur.

Acute Respiratory Distress Syndrome: Hydrochlorothiazide in AA-AMILZIDE can cause sudden respiratory toxicity, called Acute Respiratory Distress Syndrome (ARDS)

- Treatment with hydrochlorothiazide can lead to pulmonary edema, buildup of fluid in lungs, within minutes to hours after taking the medicine.
- Talk to your healthcare professional immediately if you experience sudden onset in difficulty or labored breathing, fever, and low blood pressure (e.g. dizziness or lightheadedness). Stop taking AA-AMILZIDE and seek immediate medical help.

Pregnancy: It is not known if AA-AMILZIDE can harm an unborn baby. AA-AMILZIDE is not recommended during pregnancy unless your healthcare professional decides the benefits outweigh the potential risks to your baby. If you discover that you are pregnant while taking AA-AMILZIDE tell your healthcare professional right away.

Breast-feeding: AA-AMILZIDE passes into breast milk and may harm your baby. Do not breast-feed while you are taking AA-AMILZIDE. Talk to your healthcare professional about other ways to feed your baby during this time.

Blood tests and monitoring: During your treatment with AA-AMILZIDE, your healthcare professional may monitor:

- your kidney function
- your blood pressure
- the amount of electrolytes in your blood (such as potassium, sodium, calcium)
- your liver function

Your healthcare professional will decide when to perform tests and will interpret the results.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Serious Drug Interactions

The following drugs may interact with AA-AMILZIDE:

- digoxin, used to treat heart problems.
- nonsteroidal anti-inflammatory drugs (NSAIDs) used to reduce pain and swelling, including ibuprofen, naproxen, and celecoxib.
- potassium sparing diuretics (a specific kind of “water pill” that makes your body keep potassium).
- potassium supplements.

The following may interact with AA-AMILZIDE:

- Adrenocorticotrophic hormone (ACTH), used to treat West Syndrome.
- Alcohol, barbiturates (sleeping pills), or narcotics (strong pain medications). They may cause low blood pressure and dizziness when you go from lying or sitting to standing up.
- Amphotericin B, used to treat fungal infections.
- Anticancer medications, including cyclophosphamide and methotrexate.
- Antidepressants, in particular selective serotonin reuptake inhibitors (SSRIs), including citalopram, escitalopram, and sertraline.
- Antidiabetic medications, including insulin and oral medicines.
- Bile acid resins used to lower cholesterol, including cholestyramine.
- Calcium or vitamin D supplements.
- Corticosteroids, used to treat joint pain and swelling.
- Medicines used to suppress the immune system, including cyclosporin and tacrolimus.
- Medicines that slow down or speed up bowel function, including atropine, metoclopramide, and domperidone.
- Medicines used to treat epilepsy, including carbamazepine and topiramate.
- Medicines used to treat gout, including allopurinol and probenecid.
- Lithium, used to treat bipolar disease.
- Other blood pressure lowering drugs, including angiotensin-converting enzyme (ACE) Inhibitors and Angiotensin II receptor antagonist. When taken in combination with AA-AMILZIDE, they may cause excessively low blood pressure.
- Skeletal muscle relaxants used to relieve muscle spasms, including tubocurarine.

How to take AA-AMILZIDE:

- AA-AMILZIDE is not for initial therapy. You must first be stabilized on the individual components of AA-AMILZIDE (i.e., amiloride hydrochloride and hydrochlorothiazide).
- Take AA-AMILZIDE exactly as prescribed by your healthcare professional. It is recommended to take your dose at about the same time every day.
- AA-AMILZIDE can be taken with or without food. If AA-AMILZIDE causes upset stomach, take it with food or milk.

Usual dose:

Scarring of the liver (liver cirrhosis) with fluid in the abdomen and swelling of the hands, ankles or feet: 1 tablet once a day. The maximum daily dose is 4 tablets a day.

Swelling of the hands, ankles or feet caused by heart problems: 1 or 2 tablets once a day or in divided doses. The maximum daily dose is 4 tablets a day.

High blood pressure (Hypertension): 1 or 2 tablets once a day or in divided doses. The maximum daily dose is 4 tablets a day.

Overdose:

Signs of an overdose may include:

- dehydration
- low electrolyte levels in the blood, which may cause you to feel weak, dizzy, confused, tired, have cramps or vomit.
- rapid, slow or irregular heartbeat

If you think you, or a person you are caring for, have taken too much AA-AMILZIDE, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you have forgotten to take your dose during the day, carry on with the next one at the usual time. Do not double dose.

What are possible side effects from using AA-AMILZIDE?

These are not all the possible side effects you may have when taking AA-AMILZIDE. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- muscle cramps, spasms, and pain, weakness, restlessness
- dizziness, pins and needles in your fingers, headache, being in a daze, trouble sleeping, nervousness, sleepiness, fatigue, tiredness
- constipation, diarrhea, nausea, vomiting, decreased appetite, upset stomach, enlargement of the salivary glands (glands that product saliva) in your mouth, stomach pain, hiccups, thirst, gas, bad taste, dry mouth
- reduced libido
- bleeding under the skin (bruising), rash, red patches on the skin, itching, flushing
- stuffy nose
- fever

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| COMMON | | | |
| Urticarial reaction: skin with red spots which burn, itch or sting | √ | | |
| UNCOMMON | | | |
| Allergic Reaction: difficulty swallowing or breathing, | | | √ |

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| wheezing, drop in blood pressure, feeling sick to your stomach and throwing up, hives or rash, swelling of the face, lips, tongue or throat. | | | |
| Angina (not enough oxygen to the heart muscle): discomfort in the shoulder, arm, back, throat, jaw or teeth; pain or pressure in the chest | | | √ |
| Dehydration (dry mouth, excessive thirst): thirst, headache, loss of appetite, feel tired and weak, lack of sweating, decreased blood pressure and urine, dark yellow urine | √ | | |
| Depression (sad mood that won't go away): difficulty sleeping or sleeping too much, changes in appetite or weight, feelings of worthlessness, guilt, regret, helplessness or hopelessness, withdrawal from social situations, family, gatherings and activities with friends, reduced libido (sex drive) and thoughts of death or suicide. If you have a history of depression, your depression may become worse | | √ | |
| Dysuria: difficulty and pain when passing urine | √ | | |
| Gastrointestinal (GI) bleeding (bleeding anywhere along the GI tract between mouth and anus): blood in vomit, black tarry stool, bright red blood in your stool or coming from | | √ | |

| Serious side effects and what to do about them | | | |
|--|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| rectum, rapid pulse, low blood pressure, low urine flow, confusion, weakness, dizziness | | | |
| Gout: Sudden, severe attacks of pain, swelling, redness and tenderness in one or more joints, most often in the big toe | √ | | |
| Hypotension (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, fatigue (may occur when you go from lying or sitting to standing up) | √ | | |
| Impotence: inability to have or maintain an erection | | √ | |
| Kidney disorder: nausea, vomiting, fever, swelling of extremities, fatigue, thirst, dry skin, irritability, dark urine, increased or decreased urine output, blood in the urine, rash, weight gain (from retaining fluid), loss of appetite, abnormal blood test results, mental status changes (drowsiness, confusion, coma) | | √ | |
| Malaise: Feeling of discomfort | √ | | |
| Mental confusion: problems with short-term memory, difficulty carrying out tasks, poor attention span, difficulty following a conversation | √ | | |
| Tachycardia (abnormally fast heartbeat): dizziness, light headedness, shortness of breath, racing heart | | √ | |
| Vertigo (a sense of spinning dizziness) | | √ | |

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| RARE | | | |
| <p>Electrolyte Imbalance:</p> <p>Hypokalemia (low level of potassium in the blood): muscle weakness, muscle spasms, cramping, constipation, feeling of skipped heart beats or palpitations, fatigue, tingling or numbness</p> <p>Hyperkalemia (high levels of potassium in the blood): feeling of skipped heart beats or palpitations, shortness of breath, chest pain, nausea, vomiting, numbness or tingling in the hands, feet or lips, shortness of breath, or weakness or heaviness of the arms or legs</p> <p>Hypochloremia (low levels of chloride in the blood): dry mouth, thirst, nausea, vomiting, weakness, drowsiness, restlessness, seizures or fits, confusion, headache, muscle pains or cramps, dizziness, lightheadedness or fainting</p> | | √ | |
| VERY RARE | | | |
| <p>Acute Respiratory Distress Syndrome (ARDS): severe difficulty breathing, including shortness of breath at rest or with activity, rapid breathing, wheezing or cough</p> | | | √ |
| UNKNOWN | | | |
| <p>Agranulocytosis (decrease in white blood cells): frequent infection with fever, chills, sore throat</p> | | √ | |

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| Anemia (decreased number of red blood cells): fatigue, loss of energy, looking pale, shortness of breath, weakness | | √ | |
| Blood and lymphatic system disorder: bruising or bleeding for longer than usual if you hurt yourself, fatigue and weakness, infections, fever, aches, pains, and flu-like symptoms. | | √ | |
| Eye problems: Choroidal effusion: blind spots, eye pain, blurred vision. Myopia: sudden near sightedness or blurred vision. Glaucoma: increased pressure in your eyes, eye pain. | | | √ |
| Glycosuria (sugar in urine) | | √ | |
| Hepatic encephalopathy (a nervous system disorder): forgetfulness, confusion, irritability, sleeping during the day and being awake at night, tremors | | | √ |
| Hyperglycemia: (high blood sugar): increased thirst, frequent urination, dry skin, headache, blurred vision and fatigue | √ | | |
| Hyperuricemia (high blood levels of uric acid, gout): severe joint pain, stiffness, redness and swelling | | √ | |
| Jaundice (build up of bilirubin in the blood): yellowing of the skin and eyes, dark urine, light coloured stool, itching all over your body | | √ | |

| Serious side effects and what to do about them | | | |
|---|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| Necrotizing angitis (inflammation of the blood vessels): fever, stomach pain, numbness and tingling in the hands and feet, swelling in the hands, ankles or feet, changes in frequency of urination | | | √ |
| Non-melanoma skin cancer: lump or discoloured patch on the skin that stays after a few weeks and slowly changes. Cancerous lumps are red/pink and firm and sometimes turn into ulcers. Cancerous patches are usually flat and scaly | | √ | |
| Pancreatitis (inflammation of the pancreas): upper abdominal pain, fever, rapid heart beat, nausea, vomiting, tenderness when touching the abdomen | | √ | |
| Photosensitivity (sensitivity to sunlight): itchy, red skin when exposed to sunlight | √ | | |
| Pneumonitis (inflammation of the lung tissue): shortness of breath, cough, fatigue, loss of appetite, unintentional weight loss | | √ | |
| Stomach ulcer: heartburn, long lasting stomach pain, loss of appetite and weight loss | | √ | |

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature (15°C to 30°C).

Keep out of reach and sight of children.

If you want more information about AA-AMILZIDE:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>). Find the Patient Medication Information on the manufacturer's website (<https://www.aapharma.ca/en/>), or by calling 1-877-998-9097.

This leaflet was prepared by AA Pharma Inc. 1165 Creditstone Road Unit #1, Vaughan, Ontario, L4K 4N7.

Last Revised: MAR 15, 2023